Cagrilintide

Research summary

Cagrilintide is a long-acting amylin analog studied in randomized, placebo- and active-controlled human clinical trials, both alone and combined with semaglutide, for effects on body weight in people with overweight or obesity.

In a 26-week phase 2 dose-finding trial, all tested doses of cagrilintide produced significantly greater weight loss than placebo, with the highest dose producing a mean 10.8% reduction, outperforming active comparator liraglutide. In a separate phase 2 trial combining cagrilintide with semaglutide, participants lost a mean 15.6% of body weight over 32 weeks, a result since followed up in larger phase 3 trials.

Sources: The Lancet, 2021; NEJM, 2025 (combination trials). Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.